Lexicon Pharma (LXRX) Completes LX4211 Phase 2 in Patients with Type 2 Diabetes Mellitus
Tweet Send to a Friend
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) obtained positive results from a recently completed Phase 2 study of LX4211 in patients with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
